🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase III

Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
1,266

Quick answer

Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 2 of 27

  1. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. ALPELISIB, ALPELISIB, ALPELISIB

    Ningbo Cancer Hospital

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  4. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  5. AMG 479

    Takeda

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  6. AMG 706

    Takeda

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  7. AMG386 plus PLD

    Amgen

    Fallopian Tube Cancer

    phase 3 small molecule terminated

    1 trial

  8. AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

  9. ANASTROZOLE , PALBOCICLIB , TERSOLISIB, RIBOCICLIB , EXEMESTANE , FULVESTRANT , abemaciclib, TERSOLISIB, TERSOLISIB, TERSOLISIB, LETROZOLE , TERSOLISIB, to match Tersolisib (LY4064809), STX-478

    Eli Lilly Co.

    Neoplasm Metastasis, Breast Neoplasms

    phase 3 small molecule active

    1 trial

  10. ANHYDROUS DOCETAXEL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CALCIUM LEVOFOLINATE

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  11. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Ningbo Cancer Hospital

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  12. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  13. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  16. AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  17. AZD0901

    AstraZeneca

    Gastric Cancer

    phase 3 small molecule active

    2 trials

  18. AZD8205, PACLITAXEL, DOXORUBICIN

    AstraZeneca AB

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 small molecule active

    1 trial

  19. AZD9291 80 mg/40 mg

    AstraZeneca

    Stage IB-IIIA Non-small Cell Lung Carcinoma

    phase 3 small molecule active

    1 trial

  20. Abemaciclib

    Eli Lilly and Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  21. Abemaciclib

    Eli Lilly and Company

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. Abemaciclib

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 3 small molecule active

    1 trial

  23. Abemaciclib, Lasofoxifene, Fulvestrant

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  24. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  25. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  26. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  27. Acalabrutinib

    AstraZeneca

    Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  28. Active CTC Assessment

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Prostate

    phase 3 other terminated

    1 trial

  29. Active Surveillance

    Blackmores Limited

    Muscle-Invasive Bladder Carcinoma

    phase 3 other active

    1 trial

  30. Adjuvant immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  31. Afatinib

    Boehringer Ingelheim

    Head and Neck Neoplasms

    phase 3 small molecule completed

    1 trial

  32. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  33. Afinitor 5 mg tablets, PLACEBO

    Ningbo Cancer Hospital

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  34. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  35. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  36. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  37. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  38. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  39. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

  40. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  41. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  42. Alectinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  43. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  44. Alisertib

    Takeda

    Relapsed Peripheral T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  45. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Metastatic

    phase 3 small molecule active

    1 trial

  46. Amivantamab

    Janssen Cilag International NV

    Colorectal Neoplasms

    phase 3 mab active

    1 trial

  47. Anastrozole

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  48. Anti-PD-1 antibody drug named Serplulimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Cancer (LARC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase III programs exist?

1,266 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.